Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CPI-1205||EZH2 inhibitor 18||CPI-1205 inhibits EZH2, including both wild-type and mutant forms, potentially resulting in decreased tumor growth (PMID: 27739677, PMID: 29905573).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||B-cell lymphoma||not applicable||CPI-1205||Phase I||Actionable||In a Phase I trial, CPI-1205 treatment resulted in complete response in 3% (1/32), and stable disease in 16% (5/32) of patients with B-cell lymphomas (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 420; NCT02395601).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02395601||Phase I||CPI-1205||A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas||Completed|